Miami Cancer Institute

Miami Cancer Institute Researchers Present Latest Findings at 2024 ASCO Annual Meeting

April 30, 2024

MIAMI, FL & CHICAGO, IL – April 30, 2024 – Miami Cancer Institute, part of Baptist Health South Florida, announced it will give two oral and ten poster presentations in addition to one educational session at this year’s annual meeting of the American Society of Clinical Oncology (ASCO), May 31 – June 4, at McCormick Place in Chicago, Illinois. The presentations will cover the latest research in the treatment of glioblastoma and brain metastases, breast cancer, and HPV-related cancers.

“The number and quality of our Miami Cancer Institute presentations at this year’s ASCO annual meeting is outstanding,” said Manmeet Singh Ahluwalia, M.D., MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research. “We are excited that my colleagues and I have the opportunity to share the latest results from our research into hard-to-treat forms of brain cancer such as glioblastoma, aggressive forms of breast cancer, bladder cancer, lung cancer, brain metastases, and the latest on cancers caused by the human papillomavirus, also known as HPV.”

Miami Cancer Institute’s presentations at ASCO 2024 include:

Oral Presentations

Sunday, June 2, 2024

Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)

Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO

Time: 11:36 a.m. – 11:42 a.m. CT

Location: E350

 

Monday, June 3, 2024

Results from METIS (EF-25), an International, Multicenter Phase III Randomized Study Evaluating the Efficacy and Safety of Tumor Treating Fields (TTFields) Therapy in NSCLC Patients with Brain Metastases

Presenter: Minesh P. Mehta, M.D.

Time: 10:24 a.m. – 10:36 a.m. CT

Location: S100bc

 

Poster Presentations

Saturday, June 1, 2024

A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR)

Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 388a

 

A multicenter, randomized controlled Phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE)

Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 393a

 

A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION)

Presenter: Rupesh R. Kotecha, M.D.

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 390a

 

A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE)

Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 392b

 

A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)

Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 371

 

Sunday, June 2, 2024

Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

Presenter: Vivek Podder, MBBS

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 14

 

Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study

Presenter: Rohan Garje, M.D.

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 451

 

Survival outcomes of small cell variant bladder cancer: Analysis from nationwide study

Presenter: Mohammad Arfat Ganiyani, MBBS

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 301

 

Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis.

Presenter: Vivek Podder, MBBS

Time: 09:00 a.m. – 12:00 p.m. CT

Location: Hall A

Poster #: 256

 

Monday, June 3, 2024

Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis

Presenter: Shreyas S Bellur, MBBS

Time: 01:30 p.m. – 04:30 p.m. CT

Location: Hall A

Poster #: 433

 

Education Session

Monday, June 3, 2024

Radiation Therapy Should Be the Default Standard of Care Option for Patients With Brain Metastases

Presenter: Minesh P. Mehta, M.D.

Time: 01:30 – 01:45 p.m. CT

Location: E350

In addition, researchers from Miami Cancer Institute such as Dr. Noah Kalman, Dr. Ana Sandoval Leon and Dr. Naomi Dempsey will also give more than half a dozen online presentations.

For updates from the 2024 ASCO Annual Meeting, look for #ASCO24 on social media and follow Miami Cancer Institute on X (Twitter) at @MiamiCancerInst.

In addition to the on-site presentations at ASCO 2024, Miami Cancer Institute’s Dr. Manmeet Ahluwalia and Dr. Reshma Mahtani will be available for interviews on the following respective studies, where they served as senior authors.

Activating HR+/HER2- and Triple Negative Breast Cancer Care Teams and Their Patients In Shared Decision-Making

Senior Author: Reshma Mahtani, D.O.

 

Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO

 

Phase 1 Study of BDTX-1535, an Oral 4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent Glioblastoma: Preliminary Dose Escalation

Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO

 

Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis.

Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO

 

About Miami Cancer Institute

Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://baptisthealth.net/services/cancer-care/miami-cancer-institute.

Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.

 

###

Language Preference / Preferencia de idioma

I want to see the site in English

Continue In English

Quiero ver el sitio en Español

Continuar en español